Foundayo has shown average weight loss of around 12.4%
Results may be influenced by treatment adherence, lifestyle modifications, individual metabolism, growth and development (in adolescents), underlying health conditions, and emotional wellbeing
Our healthcare team is dedicated to working closely with each patient to assess their unique health needs and determine if Semaglutide GLP-1 is the right choice for them
Multiple pathophysiological mechanisms, including insulin resistance, mitochondrial dysfunction, systemic inflammation, impaired anabolic signaling and reduced physical activity, contribute to accelerated muscle loss in these conditions
Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet
